Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double‐Blind, Randomized, Placebo‐Controlled Trial

BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) reduce morbidity and mortality in heart failure with reduced ejection fraction (HFrEF). Their role in patients without heart failure, particularly in patients with coronary artery disease (CAD) and preserved EF, is still a matter of debate. H...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cardiol
Main Authors: Sudano, Isabella, Naegele, Matthias, Roas, Susanne, Périat, Daniel, Frank, Michelle, Kouroedov, Alexey, Noll, Georg, Lüscher, Thomas F., Enseleit, Frank, Ruschitzka, Frank, Flammer, Andreas J.
Formato: Artigo
Idioma:Inglês
Publicado: Wiley Periodicals, Inc. 2016
Assuntos:
Clinical Investigations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6490773/
https://ncbi.nlm.nih.gov/pubmed/26991772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22528
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares